SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for neurofibromatosis alive. This method could work for “every rare disease under ...
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...
President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare ...
MoneyWeek on MSN6d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in ...
FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...
Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...
Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...
In this week’s edition of the biotech bi-weekly, learn more about CRAIC technologies’ 5D Spectral Surface Mapping solution, ...
An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...
Prior to that, in a deal worth up to $1 billion signed in 2023, Pfizer sold its preclinical gene therapy programs and related technologies to AstraZeneca’s rare disease unit Alexion as part of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback